NASDAQ$CRBU
Caribou Biosciences Inc · Q1 2023 earnings
Q1 2023 earnings · · Investor relations
Briefing
Caribou Biosciences reported financial results for the first quarter of 2023 and reviewed recent pipeline progress.
Caribou Biosciences reported a net loss of $28.0 million for the first quarter of 2023, with $291.0 million in cash, cash equivalents, and marketable securities as of March 31, 2023. The company is advancing its pipeline of allogeneic CAR-T cell therapies, including the ongoing ANTLER trial for CB-010 and the initiation of patient dosing in the CaMMouflage trial for CB-011.
- CB-010 ANTLER Phase 1 trial enrolling second-line LBCL patients in dose expansion; plan to report dose escalation data in H2 2023
- CB-011 CaMMouflage Phase 1 trial enrolling r/r MM patients at dose level 1
- CB-012 IND application for r/r AML planned for H2 2023
- $291.0 million in cash, cash equivalents, and marketable securities as of March 31, 2023; cash runway to fund the current operating plan into 2025
Headline financials
Revenue & EPS history
Caribou Biosciences · Revenue · Quarterly
$3.5M
Revenue by segment
Caribou Biosciences · $3.76M total across 1 segment · Q2 2023
- Licensing & collaboration$3.76M-10.6%100.0%
Forward guidance
Caribou anticipates several milestones in 2023, including providing a safety and efficacy update from the ANTLER Phase 1 clinical trial for CB-010 in H2 2023, providing updates on dose escalation as the CaMMouflage Phase 1 clinical trial for CB-011 advances, and submitting an IND application for CB-012 in H2 2023.
Tailwinds
- CB-010: Caribou plans to provide a safety and efficacy update in H2 2023 from the ongoing ANTLER Phase 1 clinical trial in r/r B-NHL, including data from at least 15 patients from dose escalation with a minimum of six months follow up.
- CB-011: Caribou plans to provide updates on dose escalation as the CaMMouflage Phase 1 clinical trial in r/r MM advances.
- CB-012: Caribou plans to submit an IND application for r/r AML in H2 2023.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q1 2023
-0.8%
Avg return
Earnings day
+0.9%
Avg return
5 days after
-5.2%
Avg return
30 days after
53%
10 / 19 earnings
Positive
+11.1%
Q2 2021
Best reaction
-32.3%
Q4 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -4.1% | +4.1% | -1.5% | |
| Q4 2025 | +6.5% | +15.2% | +13.5% | |
| Q3 2025 | -12.1% | -17.3% | -20.8% | |
| Q1 2025 | +10.5% | +16.7% | +19.4% | |
| Q4 2024 | +0.1% | -8.6% | -22.2% | |
| Q3 2024 | +8.6% | +9.0% | -16.8% | |
| Q2 2024 | -3.1% | -0.8% | -6.4% | |
| Q1 2024 | -8.6% | -7.6% | -45.4% | |
| Q4 2023 | -32.3% | -27.6% | -41.4% | |
| Q3 2023 | -5.0% | -19.3% | +24.7% | |
| Q2 2023 | +5.2% | +5.8% | -12.0% | |
| Q1 2023 | +9.3% | -2.1% | +4.0% | |
| Q4 2022 | -11.8% | -11.4% | -9.9% | |
| Q3 2022 | +3.9% | +15.0% | +2.4% | |
| Q2 2022 | +10.1% | +17.3% | +40.7% | |
| Q1 2022 | -0.5% | +22.4% | +23.7% | |
| Q4 2021 | +2.6% | -5.6% | -16.1% | |
| Q3 2021 | -4.9% | -0.5% | -18.2% | |
| Q2 2021 | +11.1% | +12.3% | -17.3% | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro